RT Journal Article
SR Electronic
T1 Prevalence of SARS-CoV-2 among high-risk populations in Lomé (Togo) in 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.07.20163840
DO 10.1101/2020.08.07.20163840
A1 Halatoko, Wemboo Afiwa
A1 Konu, Yao Rodion
A1 Gbeasor-Komlanvi, Fifonsi Adjidossi
A1 Sadio, Arnold Junior
A1 Tchankoni, Martin Kouame
A1 Komlanvi, Koffi Segbeaya
A1 Salou, Mounerou
A1 Dorkenoo, Ameyo Monique
A1 Maman, Issaka
A1 Agbobli, Amétépé
A1 Wateba, Majesté Ihou
A1 Adjoh, Komi Séraphin
A1 Akue, Edem Goeh
A1 Kao, Yem-bla
A1 Kpeto, Innocent
A1 Pana, Paul
A1 Kinde-Sossou, Rebecca
A1 Tamekloe, Agbeko
A1 Nayo-Apetsianyi, Josée
A1 Assane, Simon-Pierre Hamadi
A1 Prince-David, Mireille
A1 Awoussi, Sossinou Marcel
A1 Djibril, Mohaman
A1 Mijiyawa, Moustafa
A1 Dagnra, Anoumou Claver
A1 Ekouevi, Didier Koumavi
YR 2020
UL http://medrxiv.org/content/early/2020/08/07/2020.08.07.20163840.abstract
AB Objective This survey aims at estimating the prevalence of SARS-CoV-2 in high risk populations in Lomé.Methods From April 23rd to May 8th 2020, we recruited a random sample of participants from five sectors: healthcare, air transport, police, road transport and informal. We collected oropharyngeal swab for direct detection through real time reverse transcription polymerase chain reaction (rRT-PCR), and blood for antibodies detection by serological tests. The overall prevalence (current and past) of infection was defined by positivity for both tests.Results A total of 955 participants with a median age of 36 (IQR 32-43) were included and 71.6% (n=684) were men. Around 22.1% (n=212) were from the air transport sector, 20.5% (n=196) in the police, and 38.7% (n=370) in the health sector. Seven participants (0.7%, 95% CI: 0.3-1.6%) had a positive rRT-PCR at the time of recruitment and nine (0.9%, 95% CI: 0.4-1.8%) were seropositive for IgM or IgG against SARS-CoV-2. We found an overall prevalence of 1.6% (n=15), 95% CI: 0.9-2.6%.Conclusion The prevalence of the SARS-CoV-2 infection among high-risk populations in Lomé was relatively low and could be explained by the various measures taken by the Togolese government. Therefore, we recommend targeted screening.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Bioethics Committee for Health Research from the Togo Ministry of Health (No. 004/2020/CBRS)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available on request by sending an email to authors.95% CI95% confidence intervalIQRinterquartile range